Larimar Therapeutics, Inc.
LRMRHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframePart of the healthcare sector, Larimar Therapeutics, Inc. (LRMR) is listed under Biotechnology. Valued at $244.1M, LRMR is a micro-cap name in its sector. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease.
Market Cap
$244.1M
Beta
0.69
P/E (TTM)
—
P/E (Fwd)
-2.22
EPS (TTM)
$-1.99
EPS (Fwd)
$-1.06
ROE
-139.6%
ROA
-71.0%
Cash
$156.3M
Total Debt
$5.0M
Free CF
-$94.2M
52W Change
-44.2%
Annual Financials
Cash vs Debt
Where LRMR stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, LRMR finished 44.79% below its 150-day moving average ($3.84) and 44.94% below its 200-day moving average ($3.85). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is LRMR overbought or oversold?
At the October 20, 2026 close, LRMR's RSI(14) was 13.6, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $156.3M in cash comfortably exceeding the $5.0M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$94.2M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -139.6%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
LRMR's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. With cash comfortably exceeding debt, LRMR has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing LRMR.